| Autor: |
Jan C. Brase, Judith Prinzler, Karsten Weber, Jan Budzies, R Kronenwett, F. Haufe, Manfred Dietel, Christoph Petry, B. M. Müller, Carsten Denkert |
| Rok vydání: |
2012 |
| Předmět: |
|
| Zdroj: |
Annals of Oncology. 23:ii28 |
| ISSN: |
0923-7534 |
| DOI: |
10.1016/s0923-7534(19)65710-8 |
| Popis: |
Introduction The EndoPredict (EP) has been recently introduced as a novel RNA-based multigene test to predict the likelihood of distant recurrence in ER-positive, HER2-negative breast cancer patients solely treated with adjuvant endocrine therapy. This study was designed to compare the performance of the EP between core biopsies and surgical breast cancer specimen. Additionally, we analyzed the influence of biopsy-induced tissue injuries on the test result. Methods 80 formalin-fixed paraffin-embedded (FFPE) tumor samples comprising paired biopsies and corresponding surgical specimen from 40 ER-positive, HER2-negative patients were evaluated. Total RNA was extracted from FFPE samples using a fully automated isolation method. The EP score was determined for the biopsy and tumor section, respectively. Results Mean Ct (cycle threshold) value of 3 housekeeping genes was used as surrogate marker for RNA yield. With a median difference of 2 Ct units, RNA yield was considerably lower in core biopsies, but sufficient to measure the multigene assay in all recruited samples. The EP score was highly correlated between tumor sections and core biopsies (Pearson r = 0.92) with an excellent concordance of classification into low or high risk of metastasis (overall agreement = 95%). Biopsy-induced tissue injury had no noticeably influence on the RNA levels of the genes included in the EP. Conclusions The measurements are comparable between core biopsies and surgical sections. Core biopsies appear to be a valid starting material to run the EndoPredict. There was no evidence for a considerable effect of preoperative biopsy sampling on the EP-based risk assessment in this cohort. Disclosure J.C. Brase and F. Haufe: Employment - Sividon Diagnostics GmbH. K.E. Weber, C. Petry and R. Kronenwett: Employment, shareholder - Sividon Diagnostics GmbH. M. Dietel and C. Denkert: Shareholder - Sividon Diagnostics GmbH. All other authors have declared no conflicts of interest. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
